HPV 16/18 E6 oncoprotein has been evaluated as a useful biomarker with prognostic abilities as it can detect pre-cancer and cancerous states of cervical cancer progression. A positive E6 assay indicates a high correlation to the cervical cancerous phenotype, not the potential for cervical cancer, thus high specificity in triaging patients during screening. E6 levels of expression associate directly with the severity of cervical intraepithelial neoplasia (CIN) lesions and the risk of

According to global cancer statistics GLOBOCAN, carcinoma of cervix is ranked as the fourth most common malignancy among women worldwide with an estimation of 570,000 cases and 311,000 deaths in 2018. It is the second most common female malignancy in Lowand- Middle Income Countries (LMICs). In Kenya, the prevalence is 25 cases per 100,000 women. Approximately 75% cases of cervical cancer are caused by persistent infections of the cervical mucosal epithelium with carcinogenic types of human papillomaviruses (HPVs) mainly 16 and 18.

According to the World Health Organization (WHO), the human papillomavirus (HPV) affects more than 600 million people worldwide, being the most common sexually transmitted disease (STD). There were over 250,000 deaths due to cervical cancer worldwide and most of them took place in developing countries (WHO). There are more than 80 HPV types and more than 40 infect the genital tract

The dentist is often the first person who has the opportunity to detect mucosal alterations, such as ulcerations or white and red lesions in the oral cavity. Early diagnosis and proper management can prevent unfavorable outcomes in these patients. Indeed, chronic mucosal trauma resulting from sharp teeth and faulty restorations has

“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”